Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20436310 | 0.89 | NLRP3 (0.36) | MAPTALDH1A1MAPK1NPC1LMNA | |
| SCHEMBL20436314 | 0.84 | ITGB1 (0.37) | MAPTALDH1A1MAPK1NPC1LMNA | |
| SCHEMBL20436317 | 0.81 | CRHR1 (0.37) | MAPTALDH1A1NPC1LMNARAB9A | |
| SCHEMBL20458582 | 0.74 | CHRM3 (0.35) | MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL24200370 | 0.70 | PARP14 (0.44) | MAPTALDH1A1MAPK1NPC1LMNA | |
| SCHEMBL20421656 | 0.69 | ALDH1A1 (0.50) | MAPTALDH1A1MAPK1LMNAHSD17B10 | |
| SCHEMBL4403976 | 0.69 | ITGB1 (0.55) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20436323 | 0.67 | MAPT (0.49) | MAPTALDH1A1MAPK1LMNAALOX15 | |
| SCHEMBL24200372 | 0.66 | LMNA (0.34) | MAPTALDH1A1LMNAL3MBTL1NLRP3 | |
| SCHEMBL20436324 | 0.66 | ALDH1A1 (0.47) | MAPTALDH1A1MAPK1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11327060-B2 | Method for analyzing enantiomer | AJINOMOTO CO., INC. (JP) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11327060-B2 | Method for analyzing enantiomer | DCX, INF2, SRD5A2 | MAPT 3206/4885ALDH1A1 834/4885MAPK1 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.